scispace - formally typeset
G

Giovanna Poce

Researcher at Sapienza University of Rome

Publications -  62
Citations -  1777

Giovanna Poce is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Antimycobacterial & Mycobacterium tuberculosis. The author has an hindex of 21, co-authored 57 publications receiving 1421 citations. Previous affiliations of Giovanna Poce include Harvard University & University of Cagliari.

Papers
More filters
Journal ArticleDOI

MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212

TL;DR: The screening of genomic libraries and whole-genome sequencing found that all the characterized mutants showed mutations in the mmpL3 gene, allowing us to conclude that resistance to BM212 maps to the MMPL3 protein, a member of the MmpL (mycobacterial membrane protein, large) family.
Journal ArticleDOI

MmpL3 is the flippase for mycolic acids in mycobacteria

TL;DR: This study established the role of an essential membrane protein as the flippase for MAs and demonstrated that this protein is a direct target of an antimycobacterial compound and provides fundamental insights into OM biogenesis and MA transport in mycobacteria.
Journal ArticleDOI

Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity.

TL;DR: The design and synthesis of new analogues of 1,5-chlorophenyl)-2-methyl-3-(4-methylpiperazin-1-yl)methyl-1H-pyrrole (BM212) are reported, showing that, although some nontuberculosis mycobacterial strains were found to be sensitive, MIC values were higher than those found toward MTB.
Journal ArticleDOI

1,5-Diphenylpyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings.

TL;DR: The most active derivatives of new derivatives of 1,5-bis(4-chlorophenyl)-2-methyl-3-(4-methylpiperazin-1-yl)methyl-1H-pyrrole showed activity between 0.125-0.5 microg/mL and protection index higher than 16 and similar to isoniazid and streptomycin.